Select a medication above to begin.
Fabhalta
iptacopan
Black Box Warnings .
Appropriate Use
restricted distribution program (FABHALTA REMS) due to risk of serious infections caused by encapsulated bacterial; prescribers and pharmacies must be certified and enroll at 1-833-993-2242 or www.FABHALTA-REMS.com
Serious Infections
may occur, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B; life-threatening and fatal cases have occurred with complement inhibitors; may become rapidly life-threatening or fatal if not recognized and treated early; complete or update vaccination for encapsulated bacteria at least 2wk before tx start, unless tx delay risks outweigh serious infection risk; give antibacterial prophylaxis if urgent tx indicated in patient not up to date with vaccines, and administer vaccines ASAP; comply with ACIP recommendations for vaccinations against encapsulated bacteria in patients receiving a complement inhibitor; revaccinate per ACIP recommendations, considering tx duration; patients at incr. risk for invasive disease caused by encapsulated bacteria even if antibodies developed after vaccination; monitor for early signs of serious infection and evaluate immediately if infection suspected
Adult Dosing .
Dosage forms: CAP: 200 mg
Restricted Distribution in US
- [1-833-993-2242 or www.FABHALTA-REMS.com for more info]
paroxysmal nocturnal hemoglobinuria
- [200 mg PO bid]
- Info: if switching from eculizumab, initiate 1st iptacopan dose within 1wk after last eculizumab dose; if switching from ravulizumab, initiate 1st iptacopan dose within 6wk after last ravulizumab dose; do not open/crush/chew cap
IgA nephropathy, primary
- [200 mg PO bid]
- Info: for patients with rapid progression risk; do not open/crush/chew cap
complement 3 glomerulopathy
- [200 mg PO bid]
- Info: do not open/crush/chew cap
renal dosing
- [see below]
- eGFR >25: no adjustment; eGFR <25: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class C: avoid use
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- encapsulated bacterial infection, active serious
- N. meningitidis infection, active serious
- Streptococcus pneumoniae infection, active serious
- Haemophilus influenzae infection, active serious
- patients unvaccinated against N. meningitidis
- patients unvaccinated against Streptococcus pneumoniae
- hepatic impairment, Child-Pugh Class C
- avoid: breastfeeding during tx and x5 days after D/C
- caution: systemic infection, active
- caution: upon D/C (paroxysmal nocturnal hemoglobinuria use)
Drug Interactions .
Overview
iptacopan
complement inhibitor
- CYP2C8 substrate
- immunomodulatory effects
Contraindicated
- BCG live intravesical
- talimogene laherparepvec
Avoid/Use Alternative
- cladribine oral
- etrasimod
- gemfibrozil
- natalizumab
- pimecrolimus topical
Monitor/Modify Tx
- carfilzomib
- everolimus
- mitomycin
- sipuleucel-T
Caution Advised
- abatacept
- abemaciclib
- abrocitinib
- acalabrutinib
- adalimumab
- afamitresgene autoleucel
- aldesleukin
- alemtuzumab
- anakinra
- anifrolumab
- anti-thymocyte globulin
- atidarsagene autotemcel
- avacopan
- axicabtagene ciloleucel
- azacitidine
- azathioprine
- baricitinib
- basiliximab
- beclomethasone inhaled
- beclomethasone nasal
- belatacept
- belimumab
- belinostat
- bendamustine
- betamethasone
- bimekizumab
- blinatumomab
- bortezomib
- brentuximab vedotin
- brexucabtagene autoleucel
- brodalumab
- budesonide
- budesonide inhaled
- budesonide nasal
- budesonide rectal
- busulfan
- cabazitaxel
- canakinumab
- carbamazepine
- carboplatin
- carmustine
- certolizumab pegol
- chlorambucil
- ciltacabtagene autoleucel
- cisplatin
- cladribine injection
- clobetasol ophthalmic
- clofarabine
- coccidioides immitis skin test antigen
- copanlisib
- corticotropin
- cortisone
- crovalimab
- cyclophosphamide
- cyclosporine
- cytarabine
- dactinomycin
- danicopan
- daratumumab
- daunorubicin
- decitabine
- deflazacort
- delgocitinib topical
- deucravacitinib
- deuruxolitinib
- dexamethasone
- dexamethasone ophthalmic
- difluprednate ophthalmic
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- docetaxel
- doxorubicin
- dupilumab
- duvelisib
- eculizumab
- efgartigimod alfa
- elivaldogene autotemcel
- elotuzumab
- elranatamab
- emapalumab
- epcoritamab
- epirubicin
- eribulin
- etanercept
- etoposide
- etuvetidigene autotemcel
- fingolimod
- floxuridine
- fludarabine
- fludrocortisone
- flunisolide nasal
- fluocinolone intravitreal
- fluorometholone ophthalmic
- fluticasone furoate
- fluticasone propionate
- fruquintinib
- gemtuzumab ozogamicin
- glofitamab
- golimumab
- guselkumab
- hydrocortisone
- hydrocortisone ophthalmic
- hydroxyurea
- ibritumomab tiuxetan
- ibrutinib
- icotrokinra
- idarubicin
- idecabtagene vicleucel
- idelalisib
- ifosfamide
- inebilizumab
- infliximab
- inotuzumab ozogamicin
- irinotecan
- isatuximab
- ixabepilone
- ixekizumab
- lebrikizumab
- leflunomide
- lenalidomide
- lifileucel
- linvoseltamab
- lisocabtagene maraleucel
- lomustine
- loncastuximab tesirine
- loteprednol ophthalmic
- lymphocyte immune globulin, anti-thymocyte globulin
- melphalan
- mercaptopurine
- methotrexate
- methylprednisolone
- mirikizumab
- mitoxantrone
- mogamulizumab
- momelotinib
- mometasone implant
- mometasone inhaled
- mometasone nasal
- monomethyl fumarate
- mosunetuzumab
- mycophenolate mofetil
- mycophenolic acid
- nadofaragene firadenovec intravesical
- narsoplimab
- nelarabine
- nipocalimab
- obecabtagene autoleucel
- obinutuzumab
- ocrelizumab
- ofatumumab
- oxaliplatin
- ozanimod
- paclitaxel
- pegcetacoplan
- pentostatin
- pirtobrutinib
- polatuzumab vedotin
- pomalidomide
- ponatinib
- ponesimod
- pozelimab
- prednisolone
- prednisolone ophthalmic
- prednisone
- procarbazine
- quizartinib
- ravulizumab
- regorafenib
- rifampin
- rilonacept
- rilzabrutinib
- risankizumab
- ritlecitinib
- rituximab
- romidepsin
- ropeginterferon alfa-2b
- rozanolixizumab
- ruxolitinib
- ruxolitinib topical
- sarilumab
- satralizumab
- secukinumab
- selinexor
- sibeprenlimab
- siltuximab
- siponimod
- sirolimus
- sirolimus albumin-bound
- spesolimab
- sulfasalazine
- sutimlimab
- tacrolimus
- tafasitamab
- talquetamab
- tarlatamab
- teclistamab
- temozolomide
- temsirolimus
- teplizumab
- teriflunomide
- thioguanine
- thiotepa
- tildrakizumab
- tisagenlecleucel
- tocilizumab
- tofacitinib
- topotecan
- trabectedin
- tralokinumab
- triamcinolone
- tuberculin purified protein derivative
- ublituximab
- upadacitinib
- ustekinumab
- vamorolone
- vedolizumab
- venetoclax
- vilobelimab
- vinblastine
- vincristine
- vinorelbine
- voclosporin
- zanubrutinib
- zilucoplan
Adverse Reactions .
Serious Reactions
- meningococcal infection
- Streptococcus pneumoniae infection
- Haemophilus influenzae infection
- infection, serious
- hyperlipidemia
- thrombocytopenia
- hemolysis upon D/C (paroxysmal nocturnal hemoglobinuria use)
Common Reactions
- viral infection
- headache
- nasopharyngitis
- diarrhea
- abdominal pain
- bacterial infection
- nausea
- arthralgia
- dyslipidemia
- thrombocytopenia
- dizziness
- HTN
- rash
Safety/Monitoring .
Monitoring Parameters
Paroxysmal Nocturnal Hemoglobinuria: lipid panel; signs/symptoms of serious infection during tx and x2wk after D/C; Hgb, LDH, signs/symptoms of hemolysis for at least 2wk after D/C
IgA Nephropathy and Complement 3 Glomerulopathy: lipid panel; signs/symptoms of serious infection during tx and x2wk after D/C
Pregnancy/Lactation .
Pregnancy
Clinical Summary
benefits outweigh risks during pregnancy; inadequate human data available; no known risk of embryo-fetal toxicity based on animal data at 4-6x MRHD
Lactation
Clinical Summary
avoid breastfeeding during tx and x5 days after D/C; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: for iptacopan: oxidation, N-dealkylation, O-deethylation, dehydrogenation, glucuronidation; CYP450: 2C8 (primary), 2D6 substrate; UGT: 1A1, 1A3, 1A8 substrate
Excretion: for iptacopan: feces 72% (17% unchanged), urine 25% (18% unchanged); Half-life: 25h
Subclass: Complement Inhibitors, Hematologic ; Complement Inhibitors, Nephrological
Mechanism of Action
for iptacopan: in paroxysmal nocturnal hemoglobinuria, binds alternative complement pathway factor B, regulating C3 cleavage and its downstream complement activation cascade, preventing C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis; in IgA nephropathy and complement 3 glomerulopathy, binds alternative complement pathway factor B, inhibiting alternative pathway effects
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.